Additionally, it has been shown that the opioid inactive (+)-isomers of naltrexone inhibit lipopolysaccharide-induced Toll-like Receptor 4 (TLR4) signaling, a bacterial-induced inflammatory pathway contributing to IBD [91,92]. The gene discussed is TLR4; the disease is irritable bowel syndrome.